Company Overview of Enteris BioPharma, Inc.
Unigene Laboratories Inc., Peptelligence(TM) Drug Delivery Platform and Certain Assets comprises Peptelligence™ drug delivery, recombinant manufacturing platforms, and company’s Biotechnologies Strategic Business Unit. Peptelligence offers intellectual property covering drug delivery and manufacturing technologies, peptide research and development, and proprietary know-how.
Key Executives for Enteris BioPharma, Inc.
President and Chief Financial Officer
Vice President of Business Development
Compensation as of Fiscal Year 2015.
Enteris BioPharma, Inc. Key Developments
Enteris BioPharma, Inc. Announces Board Changes
Dec 3 13
Enteris BioPharma, Inc. announced the appointment of Steven J. Brickner, Ph.D., Jonathan Chernoff, MD, Ph.D., and Waleed Danho, Ph.D to the company's Scientific Advisory Board. Dr. Brickner joins Enteris' Scientific Advisory Board as an expert in synthetic organic/medicinal chemistry and the discovery of novel antibacterial agents. Dr. Chernoff is an internationally recognized expert in signal transduction, with particular interest in the regulation of cell proliferation and movement by protein kinases and phosphatases. Currently the Chief Scientific Officer at the Fox Chase Cancer Center.
Dr. Danho joins Enteris as one of the foremost leaders in the discovery of peptide-based drugs, peptide mimetics, and conformationally restricted peptides. Most recently the Distinguished Research Leader at Hoffmann-La Roche Inc.
Enteris BioPharma, Inc. and KeyBioScience Enter Strategic Licensing Agreement
Sep 30 13
Enteris BioPharma, Inc. and KeyBioScience announced a strategic licensing agreement for Enteris' oral drug delivery and recombinant manufacturing technologies to advance the development of KeyBioScience's recently acquired family of proprietary metabolic peptides for various indications, including the treatment of Type 2 diabetes, obesity and other inflammatory conditions with high unmet medical and socioeconomic needs. For KeyBioScience, the licensing agreement signals its transition to a clinical stage company following its formation by Nordic Bioscience. Under the terms of the agreement, Enteris will license to KeyBioScience its oral drug delivery and recombinant manufacturing technologies, as well as become the exclusive provider of pre-clinical and clinical trial API and solid dosage form finished product and will receive both fee-for-service revenues and royalties based on net sales of the developed products.
Enteris BioPharma, Inc. Appoints Timothy J. Saxon as Vice President of Business Development
Aug 20 13
Enteris BioPharma, Inc. announced the appointment of Timothy J. Saxon as Vice President of Business Development. Mr. Saxon will serve as a member of Enteris' executive leadership team and lead partnering and licensing efforts to advance the clinical development and market expansion of the company's industry leading oral peptide and small molecule delivery platform. Most recently, Mr. Saxon was an Associate Partner with Alacrita Consulting where he consulted for a range of small pharma and biotech companies, providing international business development capabilities. Prior to Alacrita, Mr. Saxon was Vice President, Business Development for Arecor Ltd., a drug technology company focused on improving the delivery of proteins and biological therapies. While at Arecor, Mr. Saxon led the company's business development activities and was responsible for securing six out-licensing deals and more than a dozen collaborations with major pharma companies. Mr. Saxon's career is also highlighted by global business development positions at Novartis Pharmaceuticals and Wyeth. During his tenure at Novartis, Mr. Saxon was responsible for driving the growth of its Cardiovascular Medicine and Metabolic Dysfunction business; and at Wyeth, Mr. Saxon held numerous positions of increasing authority over a seven-year period in which he led the company's international business development and was credited with implementing innovation initiatives that enabled Wyeth to more efficiently identify and act upon new product opportunities. Mr. Saxon has also held business development positions at Sagentia Ltd., Boots Pharmaceuticals (now Abbott), and ICI Pharmaceuticals (now AstraZeneca).
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|